INOVIO is submitting a Biologics License Application (BLA) to the FDA for INO-3107, a drug candidate being developed for the treatment of Recurrent Respiratory Papillomatosis (RRP).
5 reports, 4 independent
Updated Aug 13
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 5
- Developments
- 2
- Repetition
- 80%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
INOVIO is submitting a Biologics License Application (BLA) to the FDA for INO-3107, a drug candidate being developed for the treatment of Recurrent Respiratory Papillomatosis (RRP).
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- INOVIO published trial data in The Laryngoscope, with Aaron Friedman serving as a principal investigator.Sub-event
INOVIO is seeking FDA approval for INO-3107 under its Breakthrough Therapy designation for RRP.1 source
Keep exploring
The entities involved
Coverage
Newest first; wire copies grouped- yahoo.com
- prnewswire.com
- PR NewswireINOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults Complete submission of the Biologics License Application (BLA) remains on track for 2H25 with the goal of fil
- PR NewswireINOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights On track to submit Biologics License Application (BLA) for INO-3107 in 2H25, with the goal of file acceptance by ye
- GuruFocus.comInovio Pharmaceuticals Inc (INO) Q2 2025 Earnings Call Highlights: Strategic Advances and ... Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full